SCHEMBL3418298

SCHEMBL3418298

CC(=O)Nc1ccc(-c2cc3cc(CN4CCS(=O)(=O)CC4)cc(N(C4CCCC4)C4CCCC4)c3[nH]2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
JAK1 P23458 4/20 0.38
MAPT P10636 1/20 0.37
SLC2A1 P11166 1/20 0.37
PKM P14618 1/20 0.37
DHODH Q02127 1/20 0.36
KCNH2 Q12809 2/20 0.36
GPR119 Q8TDV5 1/20 0.36
OPRM1 P35372 1/20 0.36
JAK2 O60674 2/20 0.36
TYK2 P29597 2/20 0.36
STK10 O94804 1/20 0.36
ABL1 P00519 1/20 0.36
CYP1A2 P05177 1/20 0.36
CSF1R P07333 1/20 0.36
FLT1 P17948 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3419133 0.86 EZH2 (0.40) ALDH1A1KDM4ERAB9ANPC1MAPT
SCHEMBL2999359 0.86 MEN1 (0.37) ALDH1A1KDM4EMAPTSLC2A1DHODH
SCHEMBL2995429 0.84 ALDH1A1 (0.41) ALDH1A1KDM4ERAB9ANPC1JAK1
SCHEMBL25924584 0.83 ALDH1A1 (0.48) ALDH1A1KDM4ERAB9ANPC1JAK1
SCHEMBL3011386 0.83 ALDH1A1 (0.43) ALDH1A1KDM4ERAB9ANPC1JAK1
SCHEMBL3418751 0.79 ALDH1A1 (0.40) ALDH1A1KDM4ERAB9ANPC1JAK1
SCHEMBL16427972 0.78 MOK (0.37) ALDH1A1KDM4ERAB9ANPC1JAK1
SCHEMBL3419136 0.78 CSF1R (0.41) ALDH1A1KDM4ERAB9ANPC1MAPT
SCHEMBL16427973 0.78 ALDH1A1 (0.40) ALDH1A1KDM4ERAB9ANPC1MAPT
SCHEMBL3014664 0.78 DHODH (0.38) DHODHCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150038500-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2015-02-05 US claimed
EP-2230238-B1 INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT LG LIFE SCIENCES LTD (KR) 2013-12-11 EP claimed
US-8349885-B2 Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect LG LIFE SCIENCES LTD. (KR) 2013-01-08 US claimed
US-20120270203-A1 INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT LG CHEM, LTD. (KR) 2012-10-25 US claimed
US-20100291533-A1 INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT LG LIFE SCIENCES LTD. (KR) 2010-11-18 US claimed
EP-2230238-A2 INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT LG Life Sciences Ltd. (KR) 2010-09-22 EP claimed
US-20150038500-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2015-02-05 US disclosed
EP-2230238-B1 INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT LG LIFE SCIENCES LTD (KR) 2013-12-11 EP disclosed
US-8349885-B2 Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect LG LIFE SCIENCES LTD. (KR) 2013-01-08 US disclosed
US-20120270203-A1 INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT LG CHEM, LTD. (KR) 2012-10-25 US disclosed
US-20100291533-A1 INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT LG LIFE SCIENCES LTD. (KR) 2010-11-18 US disclosed
EP-2230238-A2 INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT LG Life Sciences Ltd. (KR) 2010-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270203-A1 INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT IDO1, IDO2, INMT ALDH1A1 287/4885KDM4E 2406/4885RAB9A 3325/4885
US-20150038500-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS AQP1, EYA3, SF1 ALDH1A1 627/4885KDM4E 2455/4885RAB9A 1582/4885
US-20100291533-A1 INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT IDO1, IDO2, INMT ALDH1A1 287/4885KDM4E 2406/4885RAB9A 3325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.